Did You Know...
...that it was melting ice cream that inspired the invention of the outboard motor? It was a lovely August day and Ole Evinrude was rowing his boat to his favorite island picnic spot. As he rowed, he watched his ice cream melt and wished he had a faster way to get to the island. At that moment the idea for the outboard motor was born!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8084503 | Indene derivatives as pharmaceutical agents Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivative... | 12/27/2011 |
| 8026283 | Exo-S-mecamylamine formulation and use in treatment A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is... | 09/27/2011 |
| 7229613 | Method for lowering serum glucose A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polym... | 06/12/2007 |
| 7211589 | Atisane compounds and use thereof The present invention provides a novel compound exhibiting an excellent suppressing effect to cell injury caused by radicals and neurotoxicity induced by excitatory nuerotransmitters such as glutamate. Specifically, it provides a compound represented by the followin... | 05/01/2007 |
| 7202279 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activi... | 04/10/2007 |
| 7157477 | Aliphatic amino-substituted demethoxylated hypocrellins and their synthesis The invention involves a methods and compositions for use in photodynamic therapy. Novel perylenequinone derivatives, conjugates comprising perylenequinone derivatives and a binding agent, and methods of treatment using these compositions are disclosed. The present ... | 01/02/2007 |
| 7101916 | Exo-S-mecamylamine formulation and use in treatment A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is... | 09/05/2006 |
| 7081477 | Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa... | 07/25/2006 |
| 6979698 | Method of treating cognitive deficits in learning and memory The treatment of learning, memory, and age-related memory disorders includes administration of a nicotine antagonist. The preferred nicotine antagonists are mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer. The effective amount of the nicotine ant... | 12/27/2005 |
| 6930128 | Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa... | 08/16/2005 |
| 6849662 | Therapeutic uses for nitric oxide inhibitors The present invention is based on the discovery that nitric oxide (NO) is an important growth regulator in an intact developing organism. In particular, the present invention relates to a method of increasing in a mammal a population of hematopoietic stem cells whic... | 02/01/2005 |
| 6756504 | Sphingolipids The invention relates to compounds of the general formula (I), as defined, and to pharmaceutical compositions containing them. The compounds of formula (I) are inhibitors of various lipid-related enzymes. They can be used in reducing accumulation of sphingoli... | 06/29/2004 |
| 6734215 | Exo-S-mecamylamine formulation and use in treatment Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. Th... | 05/11/2004 |
| 6649658 | (-)-Verbenone derivatives A description is given here of novel solid and stable derivatives of (-)-verbenone having formula (I) wherein, when X=O Z=H, .dbd.CHAr, .dbd.C(OH)COOEt, .dbd.NOR; Y=H, NH2, NH3 +X1 -, NHCOAr, NHCOR, NHCONHR, NHCONHAr, X | 11/18/2003 |
| 6613771 | Method of treatment of viral infection including HIV using water soluble fullerenes A water soluble derivative of buckministerfullerene (C60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieti... | 09/02/2003 |
| 6589996 | Treatment of disorders relating to the serotonergic system A method for the treatment of disorders relating to serotonergic system in humans, for example depression and anxiety, comprising orally administering deramciclane in a daily dosage of about 20 to about 60 mg.... | 07/08/2003 |
| 6569905 | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia and atherosclerosis. Combinations disclosed include an cholesteryl ester transfer... | 05/27/2003 |
| 6531511 | 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acce... | 03/11/2003 |
| 6384083 | USE OF ADAMANTANE AMINES OR STRUCTURALLY SIMILAR COMPOUNDS FOR COMBATING BORNA DISEASE VIRUS AND FOR THE PREVENTION AND TREATMENT OF AFFECTIVE DISEASES AND OTHER DISORDERS ASSOCIATED WITH BDV INFECTIONS IN HUMANS AND ANIMALS The invention concerns the use of 1-adamantane amines (amantadines) or structurally similar compounds for combating borna disease virus infections and for treating affective diseases and disorders associated with borna disease virus infections in humans a... | 05/07/2002 |
| 6280778 | Process for preparing natural product derivatives from plants in a single step A process is disclosed, for preparing a derivative of a targeted natural product from plants. The targeted natural product is extracted from the desired part of the plant and the targeted natural product is transformed into the desired derivative(s). Both... | 08/28/2001 |
| 6271264 | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The method comprises administering a therapeutically effective amount of a spirobicyclic ammonium moiety-containing polyme... | 08/07/2001 |
| 6228890 | Use of alicyclic diamines as immunomodulators The invention discloses the use of a compound of general structural formula (I) R-NH-K-Q-K-NH-R, wherein Q is a divalent radical of formulae (II) to (V), K is a methylene group, or, when Q is a group of formula (II), K is a binding valency. R is a radical... | 05/08/2001 |
| 6197827 | Nicotine addiction treatment The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoki... | 03/06/2001 |
| 6153621 | Combined antagonist compositions Novel compositions of a combination of nicotinic, opioid, serotonergic and/or adrenergic antagonists in combination with nicotinic and opioid agonists, anti-depressants, stimulants, non-steroidal anti-inflammatory drugs, and local anesthetics, such combin... | 11/28/2000 |
| 6114392 | Agmatine, and polyaminoguanidine-bound heterocyclic compounds for neurotrauma and neurodegenerative diseases The invention relates to the use of agmatine, in the treatment of acute neurotrauma (such as stroke) and degenerative disorders of the central and peripheral nervous system (such as dementia). The invention further provides novel compounds of general formula I... | 09/05/2000 |
| 6034079 | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette... | 03/07/2000 |
| 5939425 | Method for treating a migraine The migraine-treating effectiveness of a local anesthetic drug is significantly enhanced by coadministering dextromethorphan or dextrorphan.... | 08/17/1999 |
| 5891885 | Method for treating migraine The migraine-treating effectiveness of an antimigraine drug is significantly enhanced by administering a selective 5-HT1 agonist together with dextromethorphan or dextrorphan.... | 04/06/1999 |
| 5888536 | Liposome composition containing selegilin This invention provides liposomic composition, containing as active ingredient (-)-N--dimethyl-N-(2-propynylphenylethylamine) (selegilin) and/or salt thereof. This composition contains: 0.1-40% by weight of selegilin and/or a salt thereof, 2 to 40%... | 03/30/1999 |
| 5877222 | Method for treating aids-associated dementia The invention comprises inhibiting expression of TNF- by administering an effective amount of a stabilized activated oxygen in a matrix of chlorite ions. Preferably, a pharmaceutically acceptable formulation of tetrachlorodecaoxide is used, and mor... | 03/02/1999 |
| 5658947 | Method and composition for selectively inhibiting melanoma using betalinic acid A composition and method of inhibiting tumor growth and treating malignant melanoma without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically applied to the situs ... | 08/19/1997 |
| 5652270 | Pharmaceutical compositions containing bicycloheptane ether amines and a process for the preparation thereof The invention refers to a pharmaceutical composition, a process for the preparation thereof and a novel medical use of bicycloheptane derivatives. The pharmaceutical compositions of the invention comprise a bicycloheptane derivative of the formula I ... | 07/29/1997 |
| 5576355 | Diamondoid derivatives for pharmaceutical use A method of inhibiting viruses in which a virus is contacted with diamondoid alcohol, ketone, ketone derivative, adamantyl amino acid, quaternary salt or combinations thereof which have antiviral properties. These diamondoid derivatives are shown to have ... | 11/19/1996 |
| 5506231 | Treatment of aids dementia, myelopathy and blindness Damage to CNS neurons of a human patient infected with a human immunodeficiency virus is reduced by administering an antagonist of the NMDA receptor complex.... | 04/09/1996 |
| 5001162 | Use of avarone for the control of adult T-cell leukemia/lymphoma The invention concerns the use of avarone and pharmaceutical compositions thereof for the control of adult T-cell leukemia/lymphoma.... | 03/19/1991 |
| 4942179 | Single-phase composition containing a perfluorinated oil and one or more surfactant(s), useful as an excipient for cosmetic and dermatologic formulations, as well as for biomedical applications A single-phase, either isotropic or anisotropic formulation is disclosed, which contains perfluorinated oil and one or more surfactant(s), is useful as an excipient for cosmetic and dermatologic formulations and is characterized in that at least one surfa... | 07/17/1990 |
| 4931472 | Fluorinated triethylenediamine as an oxygen transport agent Fluorinated triethylenediamine compounds such as perfluorotriethylenediamine and the novel compounds undecafluorotriethylenediamine and decafluorotriethylenediamine, prepared by indirect fluorination of triethylenediamine by passing triethylenediamin... | 06/05/1990 |
| 4888354 | Skin penetration enhancement using free base and acid addition salt combinations of active agents The invention is directed to compositions for topical application made up of active pharmaceutical permeants capable of existing in both free base and acid addition salt form. The permeants are present as a combination of both free base and acid addition ... | 12/19/1989 |
| 4812481 | Synergistic combination of amantadiene and selegiline There are provided in medicaments with synergistic action containing a combination of amantadine and selegiline.... | 03/14/1989 |
| 4788130 | 1-amino-2,3-dihydro-1H-indene compounds Novel 2,3-dihydro-1H-indene derivatives and salts thereof represented by the general formula (1), ##STR1## [wherein R1 and R2 are each a hydrogen atom, a lower alkyl group, a phenyl group which may have halogen atoms and/or alky... | 11/29/1988 |
